Mast Therapeutics (MSTX) – Analyst Ratings
-
Cowen Downgrades Mast Therapeutics (MSTX) to Market Perform
-
bluebird bio (BLUE) May Offer The Most Hope To Sickle Cell Patients...A Cure - Maxim
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MSTX Stock Lookup